NasdaqCM:BCLI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. More Details


Snowflake Analysis

Adequate balance sheet with moderate growth potential.

Share Price & News

How has Brainstorm Cell Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: BCLI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.6%

BCLI

-1.2%

US Biotechs

-1.1%

US Market


1 Year Return

180.5%

BCLI

30.7%

US Biotechs

15.6%

US Market

Return vs Industry: BCLI exceeded the US Biotechs industry which returned 30.7% over the past year.

Return vs Market: BCLI exceeded the US Market which returned 15.6% over the past year.


Shareholder returns

BCLIIndustryMarket
7 Day0.6%-1.2%-1.1%
30 Day-31.7%1.3%4.2%
90 Day-26.5%-2.5%6.3%
1 Year180.5%180.5%33.0%30.7%18.2%15.6%
3 Year139.1%139.1%19.6%13.6%39.6%30.4%
5 Year259.5%259.5%8.7%1.0%79.5%59.2%

Price Volatility Vs. Market

How volatile is Brainstorm Cell Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Brainstorm Cell Therapeutics undervalued compared to its fair value and its price relative to the market?

12.41x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BCLI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BCLI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: BCLI is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: BCLI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BCLI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BCLI is overvalued based on its PB Ratio (12.4x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Brainstorm Cell Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

74.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCLI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: BCLI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: BCLI's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if BCLI's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if BCLI's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BCLI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Brainstorm Cell Therapeutics performed over the past 5 years?

-35.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: BCLI is currently unprofitable.

Growing Profit Margin: BCLI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BCLI is unprofitable, and losses have increased over the past 5 years at a rate of 35.9% per year.

Accelerating Growth: Unable to compare BCLI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BCLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.1%).


Return on Equity

High ROE: BCLI has a negative Return on Equity (-106.58%), as it is currently unprofitable.


Next Steps

Financial Health

How is Brainstorm Cell Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: BCLI's short term assets ($30.3M) exceed its short term liabilities ($6.4M).

Long Term Liabilities: BCLI's short term assets ($30.3M) exceed its long term liabilities ($284.0K).


Debt to Equity History and Analysis

Debt Level: BCLI is debt free.

Reducing Debt: BCLI has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BCLI has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BCLI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 30.1% each year


Next Steps

Dividend

What is Brainstorm Cell Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate BCLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BCLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BCLI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BCLI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BCLI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.1yrs

Average management tenure


CEO

Chaim Lebovits (49 yo)

5.08yrs

Tenure

US$1,056,276

Compensation

Mr. Chaim Lebovits has served as the Chief Executive Officer of Brainstorm Cell Therapeutics Inc. since September 22, 2015 and had served as its President since July 3, 2007 until April 2020. Mr. Lebovits ...


CEO Compensation Analysis

Compensation vs Market: Chaim's total compensation ($USD1.06M) is below average for companies of similar size in the US market ($USD1.93M).

Compensation vs Earnings: Chaim's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Chaim Lebovits
Chief Executive Officer5.08yrsUS$1.06m0.40%
$ 1.3m
Irit Arbel
Co-Founder & Independent Vice Chair of the Board0.58yrUS$84.37k0.49%
$ 1.6m
Ralph Kern
President & Chief Medical Officer0.50yrUS$852.15k0.48%
$ 1.5m
Preetam Shah
Executive VP1.08yrsUS$882.92k0.12%
$ 373.7k
Uri Yablonka
Executive VP6.33yrsUS$44.40k0.056%
$ 179.1k
David Setboun
Executive VP & COO0.50yrno data0.17%
$ 561.6k
Yael Gothelf
Vice President of Scientific & Regulatory Affairsno datano datano data
Daniel Offen
Chief Scientific Advisorno datano datano data
Arturo Araya
Chief Commercial Officer2.08yrsUS$20.44k0.027%
$ 87.9k
Susan Ward
Head of Clinical Operations2.33yrsno datano data
Stacy Lindborg
Executive VP & Head of Global Clinical Research0.33yrno data0.079%
$ 255.3k
Anthony Waclawski
Executive VP & Global Head of Regulatory Affairs0.083yrno data0.11%
$ 357.3k

1.1yrs

Average Tenure

49yo

Average Age

Experienced Management: BCLI's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Irit Arbel
Co-Founder & Independent Vice Chair of the Board0.58yrUS$84.37k0.49%
$ 1.6m
Uri Yablonka
Executive VP6.33yrsUS$44.40k0.056%
$ 179.1k
Jacob Frenkel
Independent Chairman of the Board0.58yrno data0.18%
$ 578.6k
Harvey Krueger
Member of Business Advisory Board13.17yrsno datano data
Stanley Appel
Member of Scientific Advisory Boardno datano datano data
Andrew Card
Member of Business Advisory Board9.58yrsno datano data
Amit Bar-Or
Member of Scientific Advisory Boardno datano datano data
Malcolm Taub
Independent Director11.58yrsUS$46.68k0.17%
$ 544.5k
Rasheda Ali
Member of Business Advisory Board13yrsno datano data
Jerold Chun
Chairman of Scientific Advisory Board2.58yrsno datano data
June Almenoff
Independent Director3.67yrsUS$37.78k0.029%
$ 93.7k
Anthony Polverino
Independent Director2.67yrsUS$34.32k0.050%
$ 162.0k

5.0yrs

Average Tenure

72yo

Average Age

Experienced Board: BCLI's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.6%.


Top Shareholders

Company Information

Brainstorm Cell Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Brainstorm Cell Therapeutics Inc.
  • Ticker: BCLI
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$322.305m
  • Shares outstanding: 31.57m
  • Website: https://www.brainstorm-cell.com

Number of Employees


Location

  • Brainstorm Cell Therapeutics Inc.
  • 1325 Avenue of Americas
  • 28th Floor
  • New York
  • New York
  • 10019
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BCLINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMay 2003
GHDNDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2003

Biography

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 01:05
End of Day Share Price2020/10/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.